PMID- 26091472
OWN - NLM
STAT- MEDLINE
DCOM- 20150914
LR  - 20220408
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 94
IP  - 24
DP  - 2015 Jun
TI  - Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 
      Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration 
      Cytology FISH Experience From China.
PG  - e981
LID - 10.1097/MD.0000000000000981 [doi]
LID - e981
AB  - Estrogen receptor (ER) and progesterone receptor (PR) overexpression can be used 
      to predict patient prognosis in breast cancer (BC). Human epidermal growth factor 
      receptor 2 (HER2) is a reliable predictive marker in invasive breast cancer 
      (IBC). Thin-Prep (TP) specimens are commonly utilized for immunocytochemistry 
      (ICC) in fine needle aspiration cytology (FNAC). Thus, we sought to investigate 
      if the incorporation of molecular diagnosis performed on TP-processed specimens 
      is applicable in clinical practice. Hormone receptors (HRs) and HER2 
      immunocytochemistry was performed on 542 primary breast cancer FNAC specimens 
      using the TP method. One hundred fourteen HER2 fluorescence in situ hybridization 
      (FISH) analyses were performed on HER2 ICC 2+ FNAC specimens and the 
      corresponding tissue samples. HRs results of TP slides and those of 
      formalin-fixed paraffin-embedded (FFPE) slides were correlated well for ER 
      (concordance rate =  3.3%, kappa value = 0.85) and PR (concordance rate = 88.6%, 
      kappa value = 0.75). HER2 results for the TP slides and those of the matched FFPE 
      slides also correlated well (concordance rate = 80.0%, kappa value = 0.62). The 
      specificity of HER2 was 97.3%; however, the sensitivity was only 67.1%. 
      Cytological specimens and histological samples showed a strong correlation 
      (concordance rate = 99.1%, kappa value = 0.98) while being used to evaluate HER2 
      gene amplification. FNAC is a minimally invasive technique that can be used as an 
      alternative method to collect tissue especially in cases where an excisional or 
      core biopsy is difficult to obtain, or when recurrence is present. The results of 
      ICC HRs in FNAC TP specimens may be used instead, but HER2 assessment may not be 
      reliable enough for clinical use. FISH testing is necessary in this setting.
FAU - Zhang, Zhihui
AU  - Zhang Z
AD  - From the Department of Pathology (ZZ); Department of Medical Oncology (PY, HG, 
      LZ, JY, MW, HZ, QP, BX), Cancer Hospital, Chinese Academy of Medical Sciences and 
      Peking Union Medical College, Beijing, China.
FAU - Yuan, Peng
AU  - Yuan P
FAU - Guo, Huiqin
AU  - Guo H
FAU - Zhao, Linlin
AU  - Zhao L
FAU - Ying, Jianming
AU  - Ying J
FAU - Wang, Mingrong
AU  - Wang M
FAU - Zhao, Huan
AU  - Zhao H
FAU - Pan, Qinjing
AU  - Pan Q
FAU - Xu, Binghe
AU  - Xu B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy, Fine-Needle
MH  - Breast Neoplasms/*diagnosis/*pathology
MH  - China
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Receptor, ErbB-2/*biosynthesis
MH  - Receptors, Estrogen/*biosynthesis
MH  - Receptors, Progesterone/*biosynthesis
MH  - Sensitivity and Specificity
PMC - PMC4616547
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2015/06/20 06:00
MHDA- 2015/09/15 06:00
PMCR- 2015/06/19
CRDT- 2015/06/20 06:00
PHST- 2015/06/20 06:00 [entrez]
PHST- 2015/06/20 06:00 [pubmed]
PHST- 2015/09/15 06:00 [medline]
PHST- 2015/06/19 00:00 [pmc-release]
AID - 00005792-201506030-00025 [pii]
AID - 10.1097/MD.0000000000000981 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2015 Jun;94(24):e981. doi: 10.1097/MD.0000000000000981.